Strefford Jonathan C, An Qian, Harrison Christine J
Cancer Genomics Group, Cancer Sciences Division, University of Southampton, Southampton, UK.
Cell Cycle. 2009 Jul 15;8(14):2175-84. doi: 10.4161/cc.8.14.9103. Epub 2009 Jul 26.
Chromosomal rearrangements are recurrent findings in human cancer and result in aberrant restructuring of the genome. The majority of known fusion genes are the consequence of reciprocal (balanced) translocations. However, most translocations described in human cancer are unbalanced, suggesting that other cancer genes remain to be identified. Historically, it was assumed that these unbalanced rearrangements affected gene function through the loss or gain of chromosomal material. However, emerging data supports direct disruption of genes located at or close to the unbalanced translocation breakpoints. New approaches are required for the identification of those gene loci underlying unbalanced translocations in cancer, as traditional methods have had limited success. This review focuses on one such strategy, using traditional and innovative molecular technologies to characterize breakpoint heterogeneity within a series of acute lymphoblastic leukemia (ALL) patients with dicentric chromosomes. This approach has shown that in ALL, specific gene loci can be targeted by heterogeneous translocation breakpoints involving multiple partner chromosomes. Carcinomas have a high proportion of unbalanced rearrangements and relatively few significant genes have been identified. The application of the same strategy to their analysis will lead to the discovery of novel cancer genes and improve our understanding of the genetic basis of tumorigenesis.
染色体重排是人类癌症中反复出现的现象,会导致基因组的异常重组。大多数已知的融合基因是相互(平衡)易位的结果。然而,人类癌症中描述的大多数易位是不平衡的,这表明其他癌症基因仍有待鉴定。从历史上看,人们认为这些不平衡重排通过染色体物质的丢失或增加来影响基因功能。然而,新出现的数据支持直接破坏位于不平衡易位断点处或其附近的基因。由于传统方法取得的成功有限,因此需要新的方法来鉴定癌症中不平衡易位背后的那些基因座。本综述重点介绍一种这样的策略,即使用传统和创新的分子技术来表征一系列具有双着丝粒染色体的急性淋巴细胞白血病(ALL)患者中的断点异质性。这种方法表明,在ALL中,特定的基因座可被涉及多个伙伴染色体的异质易位断点靶向。癌组织中不平衡重排的比例很高,而已鉴定出的重要基因相对较少。将相同的策略应用于它们的分析将导致发现新的癌症基因,并提高我们对肿瘤发生遗传基础的理解。